Meadow Creek Investment Management’s Idexx Laboratories IDXX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q3
$944K Sell
3,472
-252
-7% -$70.1K 0.02% 501
2019
Q2
$1.02M Sell
3,724
-2,436
-40% -$600K 0.02% 483
2019
Q1
$1.38M Buy
6,160
+644
+12% +$133K 0.03% 385
2018
Q4
$1.03M Buy
5,516
+1,260
+30% +$258K 0.02% 421
2018
Q3
$1.06M Sell
4,256
-336
-7% -$81.6K 0.02% 452
2018
Q2
$1M Sell
4,592
-532
-10% -$110K 0.02% 434
2018
Q1
$981K Sell
5,124
-2,240
-30% -$413K 0.02% 431
2017
Q4
$1.15M Sell
7,364
-5,516
-43% -$868K 0.03% 422
2017
Q3
$2M Buy
12,880
+1,008
+8% +$159K 0.05% 297
2017
Q2
$1.92M Buy
11,872
+5,376
+83% +$873K 0.05% 301
2017
Q1
$1M Buy
6,496
+1,344
+26% +$185K 0.02% 394
2016
Q4
$604K Buy
+5,152
New +$588K 0.02% 468

Other funds holding IDXX

Meadow Creek Investment Management's IDXX Position: Q3 2019 in Review

Meadow Creek Investment Management reduced its Idexx Laboratories (IDXX) stake by 6.8% in Q3 2019, selling an estimated $70.1K and leaving 3,472 shares worth $944K. The position accounts for 0.02% of the portfolio, ranked #501.

Meadow Creek Investment Management first reported a position in IDXX in Q4 2016 and has held it in 12 quarters since. The position peaked at $2M in Q3 2017. 720 funds tracked by Wall St. Rank hold IDXX as of Q3 2019.

  • Meadow Creek Investment Management held 3,472 shares of Idexx Laboratories worth $944K as of Q3 2019.
  • Meadow Creek Investment Management sold 252 Idexx Laboratories shares in Q3 2019, an estimated $70.1K.
  • Idexx Laboratories made up 0.02% of Meadow Creek Investment Management's portfolio in Q3 2019, its #501 holding.
  • Meadow Creek Investment Management first reported a position in Idexx Laboratories in Q4 2016 and has held it in 12 quarters since.
  • Meadow Creek Investment Management's Idexx Laboratories position peaked at $2M in Q3 2017.
  • 720 funds tracked by Wall St. Rank held Idexx Laboratories as of Q3 2019.

Based on Meadow Creek Investment Management's 13F filing for Q3 2019, filed 14 Nov 2019.